

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 47/48	A1	(11) International Publication Number: WO 94/16733 (43) International Publication Date: 4 August 1994 (04.08.94)
(21) International Application Number: PCT/EP94/00205 (22) International Filing Date: 26 January 1994 (26.01.94) (30) Priority Data: MI93A000141 29 January 1993 (29.01.93) IT (71) Applicant (for all designated States except US): CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): CHIESI, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). VENTURA, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). PASINI, Massimo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). SZEJTLI, Jösef [HU/IT]; Via Palermo, 26/A, I-43100 Parma (IT). VIKMON, Maria [HU/IT]; Via Palermo, 26/A, I-43100 Parma (IT). REDENTI, Enrico [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). (74) Agent: MINOJA, Fabrizio; Studio Consulenza Brevettuale, Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HIGHLY SOLUBLE MULTICOMPONENT INCLUSION COMPLEXES CONTAINING A BASE TYPE DRUG, AN ACID AND A CYCLODEXTRIN		
(57) Abstract The invention relates to highly soluble multicomponent inclusion complexes consisting of a basic-type drug, a cyclodextrin and an acid. Said complexes are easily water soluble with extremely high concentrations both of the drug and of cyclodextrin.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HIGHLY SOLUBLE MULTICOMPONENT INCLUSION COMPLEXES
CONTAINING A BASE TYPE DRUG, AN ACID AND A CYCLODEXTRIN

The invention relates to highly soluble multicomponent inclusion complexes consisting of a basic-type drug, a cyclodextrin and an acid.

5 The term basic-type drug refers to organic compounds bearing hydrophobic groups and nitrogen basic groups, such as amino, amine and guanidino groups.

A lot of drugs bear aliphatic or aromatic amine groups. These types of drugs usually have very low aqueous solubility in base form which often hampers
10 their application.

Salt formation with inorganic or organic acids is a common method, which is very often used to increase the solubility of base-type drugs. However sometimes even the salts are poorly soluble, or by other reasons
15 a conventional salt formation is inadequate.

It is known that the aqueous solubility of base-type drugs or their salts is much higher at low pH values whereas it is very poor at higher pH of the intestinal tract, comprised between pH 5-8. Therefore,
20 the release site from formulations of such drugs is restricted to the stomach or to the upper part of the intestinal tract and such properties make impossible the preparation and use of such drugs in controlled release formulation, wherever it is necessary to ensure
25 the dissolution of the drug in the intestinal juice.

The difficulties originated from the low aqueous solubility of certain drugs, such as low rate and percent of dissolution from pharmaceutical

formulations, together with poor and/or variable bioavailability can be overcome by cyclodextrin complexation.

In prior art a lot of amine type drugs, such as terfenadine and cinnarizine, have been successfully complexed with cyclodextrins, with good results. However, low aqueous solubility of β -cyclodextrin hinders its applications as complexing agent from a technological point of view.

Soluble complexes can be prepared from homogeneous drug-cyclodextrin solutions by removing water by freeze-drying or spray drying. This technique is widely used in the prior art in case of using well soluble β -cyclodextrin derivatives such as methyl or hydroxypropyl β -cyclodextrins.

The solubilizing capacity of β -cyclodextrin is strongly limited by its low aqueous solubility. Therefore large volume of solutions have to be used for the preparation of soluble complexes.

Surprisingly, it has now been found that the presence of acids in the formation of complexes of amine type drugs with cyclodextrins results in easily water soluble complexes with extremely high concentrations both of the guest molecule and of cyclodextrin.

Even more surprisingly it has been found that, when the cyclodextrin is β -cyclodextrin, the presence of an acid considerably enhances its water solubility.

In fact, in this kind of complexes, not only the solubility of the hydrophobic guest results enhanced by several orders of magnitude, but also the solubility of

the hydrophilic β -cyclodextrin may be increased up to more than 10 times.

Up to now, a mutual host-guest solubility enhancement up to a very modest extent has been reported only in the case of fendiline hydrochloride- β -CD (Stadler Szöke A. et al..., J. Inclusion Phenomena 3, 71-84, 1985).

A first aspect of the present invention therefore relates to multicomponent inclusion complexes fundamentally consisting of a base type drug, a cyclodextrin and an acid.

A second aspect of the present invention relates to the use of an acid in the preparation of complexes with a cyclodextrin, and particularly with β -cyclodextrin, with the purpose of increasing water solubility of the cyclodextrin itself.

The solubility increase of the guest molecule and/or the cyclodextrin may occur both in the presence of inorganic acids and of organic acids.

Examples of inorganic acids are halogenhydric acids, such as hydrochloric, hydrobromic acid.

Examples of organic acids are aliphatic carboxylic acids, such as acetic acid, propionic acid, butyric acid, oxalic acid, succinic acid, glutaric acid, pimelic acid, tartaric acid, malic acid, citric acid, maleic acid, malonic acid. Particularly favourable results have been obtained with aliphatic carboxylic acids bearing one or more oxygenated substituents in the aliphatic chain, preferably keto groups or hydroxy groups. The most evident solubilizing effects have been obtained with organic acids, and among them, the best

results have been achieved with aliphatic carboxylic acids bearing one or more oxygenated substituents in the aliphatic chain, such as citric acid, tartaric acid, α -ketoglutaric acid, threonic acid.

In prior art the application of organic acids to drug complexes with cyclodextrins are very limited and concern:

- a) the improvement of chemical stability of carmofur (1-hexylcarbamoyl-5-fluorouracil, HCFU) in β -cyclodextrin complexes prepared by the kneading method with an organic acid, such as L(+)-tartaric, DL-malic, citric, maleic, malonic acid.

The organic acids can provide an acidic environment around the complex after water elimination, since HCFU is chemically stable under acidic conditions (Japanese Patent Application N° 60185772, by Mitsui; Chem Abs 104:155972 and Kikuchi M et al.. Chem Pharm Bull 35(1), 315-319, 1987);

- b) the use of a solid organic acid (selected from citric, tartaric or malic acid) in solid pharmaceutical compositions containing cephalosporins and a cyclodextrin in order to improve their dissolution and bioavailability with respect to compositions containing crystalline cellulose instead of a α -cyclodextrin (European Patent EP 163433, by Takeda; Chem Abs 105:12098n),

- c) the simultaneous administration of citric acid and cinnarizine or its complex with β -cyclodextrin to evaluate its bioavailability: however, no significant difference has been found between the

two administration forms (Tokumura T et al.. J. Incl. Phenom 2, 511-521, 1984 and Chem Pharm Bull 33(7), 2962-2967, 1988).

Up to now neither multicomponent inclusion complexes containing a cyclodextrin, a base type active ingredient and an acid have been described, nor a so high improvement of solubility of an active ingredient by complexation with a cyclodextrin has been obtained.

The simultaneous large solubility enhancement for β -CD at least up to the here disclosed extent is also a new and surprising observation.

A further object of the present invention is a general method for the preparation of base-type drug: β CD:acid complex consisting in the removal of water from the highly supersaturated solution of the components in distilled water. According to the present invention said process comprises the following steps:

- a) suspension in distilled water of suitable quantities of drug, cyclodextrin and acid ;
- b) homogenization of the suspension obtained in step a) by stirring and/or sonication to obtain a clear or slightly opalescent solution;
- c) filtration of the solution obtained in step b) by using a suitable system to obtain a clear solution;
- d) dehydration of the solution obtained in step c) by using usual dehydration methods such as freeze-drying, spray-drying, stove-drying or similar.

The same method can be used in order to prepare complexes with α -CD, γ CD, hydroxypropyl- β CD, dimethyl- β CD, RAMEB (RANDOM METHYLATED β -CD) or other

6

cyclodextrin derivatives. Even more supersaturated solutions with improved storage stability, which can be used to prepare liquid pharmaceutical compositions for oral or parenteral administration, are obtained by using these entirely more soluble CD and β CD derivatives.

Details of the invention are illustrated in the following examples.

The drugs reported in the examples, belonging to different chemical and therapeutical classes, have been selected as test molecules as considered especially representatives of the invention. Particularly surprising results have been obtained with diphenylmethane, tricyclic and azole derivatives.

Nevertheless, it is evident that the present invention is applicable to every compound bearing basic groups.

EXAMPLE 1

Preparation of terfenadine- β CD-hydroxyacid soluble complexes.

8 mmol of β CD, 4 mmol of terfenadine (TFN) and 5 mmol of tartaric acid (or 6 mmol of ascorbic acid or 4 mmol of lactic acid) were suspended in 60-70 ml of distilled water.

The suspensions were homogenized by vigorous stirring and ultrasonicated to obtain slightly opalescent solutions. After filtering the solutions across a glass prefilter, terfenadine content was determined by UV-photometry after 70 fold dilution with 50% aqueous ethanol. Concentrations of 27-29 mg/ml of dissolved terfenadine were detected.

Solid complexes were isolated from the clear solutions by freeze-drying.

The active ingredient content of the solid complexes was 15-17% (w/w) as measured by UV-photometry.

Powder X-ray analysis confirmed the formation of the complexes.

Solubility properties of the complexes.

100 mg of complexes prepared according to Example 1 were easily dissolved in 0.5 ml of distilled water resulting in clear solutions. After 30 fold dilution of the solution with 50% (v/v) ethanol, UV-photometry was used to determine the dissolved terfenadine concentration which resulted more than 30 mg TFN/ml.

Data relating to the complex obtained with tartaric acid are reported in Table 1 and those relating to the complex with citric acid in Table 2.

With a similar process, the terfenadine- β CD-glycerophosphoric acid complex (0.2/0.4/0.4 mmol) was prepared. The solubility of terfenadine with respect to said complex was 4 mg/ml.

EXAMPLE 2

Preparation of terfenadine- β CD-mono- or bicarboxylic acid complexes.

Terfenadine (2 mmol) and β CD (4 mmol) were suspended into 25 ml of distilled water. 3 mmol of acetic acid (or 4 mmol formic acid) were added and the suspension was ultrasonicated for several minutes. The resulting slightly opalescent solutions, obtained by filtration, were freeze dried.

Active ingredient content of the complexes was

determined by UV-photometry and gave $17 \pm 0.5\%$.

Redissolving properties of the complexes.

Redissolving properties of the complexes containing formic and acetic acid are also interesting: 100 mg of complex were easily dissolved in 0.5 ml of water resulting in a clear solution for the acetic acid and an opalescent solution for the formic acid- β CD complexes, respectively.

pH of these solutions resulted 4.36 for the complexes with acetic acid and 3.67 for the complexes with formic acid.

In a comparative test it was tried to dissolve 1 mmol of terfenadine into 15 ml of distilled water using 6 mmol of acetic or 4 mmol of formic acid.

The test was not successful and the highly hydrophobic terfenadine disappeared from the surface of the solution at the same time of the precipitation of the corresponding poorly soluble salt.

3.15 and 0.34 mg/ml of dissolved terfenadine were measured in the filtrate in the presence of acetic and formic acid, respectively.

With a similar process, the terfenadine- β CD- α -ketoglutaric acid complex (0.2/0.4/0.4 mmol, 1:2:2 ratio) was prepared. The solubility of terfenadine with respect to said complex was about 6 mg/ml.

EXAMPLE 3

Preparation of terfenadine- β CD-inorganic acid complexes.

Terfenadine (1 mmol), β CD (2 mmol), 1 mmol of HCl (or 1 mmol of phosphoric acid) were suspended into 15 ml of distilled water. The suspension was

ultrasonicated resulting in a slightly opalescent solution. Solid complexes were isolated by freeze-drying. Active ingredient content of the complex was $18 \pm 1\%$, as measured by UV-photometry.

Redissolving properties of the complexes.

100 mg of complexes were easily dissolved in 0.5 ml of distilled water or into HCl solution (pH 1.4) giving a clear solution. Terfenadine content of the solution was measured after 80 fold dilution with 50% (v/v) ethanol by UV-photometry. 29 mg/ml of dissolved terfenadine were measured. Addition of sodium chloride did not decrease the concentration of this highly saturated terfenadine-HCl- β CD solution.

EXAMPLE 4

Preparation of terfenadine-tartaric acid- γ CD or β CD derivative complexes.

Terfenadine (1 mmol), L(+) tartaric acid (1.5 mmol) and γ CD (2 mmol) or 2 mmol of HP β CD; or 2 mmol of DIMEB or 2 mmol of RAMEB were suspended and ultrasonicated in 15 ml of distilled water.

The use of γ CD resulted in a slightly opalescent solutions, while the solutions obtained with HP β CD, DIMEB and RAMEB were clear. In addition, these latter CDs gave clear solutions even using 7.5 ml of distilled water only. The terfenadine content in these solutions was about 50 mg/ml.

EXAMPLE 5

Preparation of cinnarizine- β CD-hydroxyacid complexes.

β CD (4 mmol), cinnarizine (2 mmol) and citric acid (3 mmol) (or tartaric acid (3 mmol)) were suspended into 20 ml of distilled water. The suspensions were

10

homogenized and ultrasonicated to obtain slightly opalescent solutions. After filtering the solution across a glass prefilter, solid complexes were isolated by freeze-drying the solutions.

5 The active ingredient content of the complexes was found to be $11 \pm 0.5\%$, as measured by UV-photometry.

Redissolving properties of the complexes.

100 mg of complexes were dissolved in 0.5 ml of distilled water resulting in almost clear and slightly opalescent solutions in case of citric and tartaric acid complexes, respectively. pH of these highly supersaturated solutions was 2.5 and 2.3 for citric and tartaric acid complexes, respectively. After filtration across a $0.45\mu\text{m}$ membrane filter, concentration of the solutions was measured after 2000 fold dilution with 50% ethanol by UV-photometry. 20-22 mg/ml of dissolved cinnarizine were measured. Calculated βCD concentration of the solutions was about 16-18% (p/v).

20 The data of the complex with tartaric acid are reported in Table 1.

EXAMPLE 6

Preparation of domperidone- βCD -tartaric acid complex.

40 mmol of domperidone, 40 mmol of tartaric acid and 40 mmol of βCD were suspended into 700 ml of water and ultrasonically stirred till a slightly opalescent solution was obtained. After filtration through a sintered glass prefilter, solid complex was isolated by freeze drying.

30 The active ingredient content of the complex was found to be $27.4 \pm 0.1\%$, as measured by UV photometry.

Redissolving properties of the complexes.

100 mg of the complex were easily dissolved in 1 ml of distilled water. Domperidone content of this solution was 25 mg/ml.

5 Solubility data are reported in Table 1.

EXAMPLE 7

Preparation of domperidone-tartaric acid-HPBCD complex.

12 mmol of domperidone, 12 mmol of tartaric acid and 22 mmol of HPBCD (substitution degree=2.8) were
10 suspended into 100 ml of distilled water and ultrasonically homogenized till a slightly opalescent solution was obtained. After filtration through a sintered glass prefilter, solid complex was isolated by freeze drying.

15 Active ingredient content: $14.0 \pm 0.2\%$, as measured photometrically.

Redissolving properties of the complex.

100 mg of complex were easily dissolved in 0.3 ml of distilled water. Domperidone content of this
20 solution was 50 mg/ml.

Solubility data are reported in Table 3.

EXAMPLE 8

Preparation of other domperidone complexes.

With a process similar to the one of the preceding
25 examples, the following complexes were prepared:

- 8a) domperidone (4.4 mmol)-BCD (4.4 mmol)-lactic acid (1.1 mmol) (1:1:2.5 ratio);
- 8b) domperidone (4.4 mmol)-BCD (4.4 mmol)-malic acid (1.1 mmol) (1:1:2.5 ratio);
- 30 8c) domperidone (0.25 mmol)-BCD (0.5 mmol)-threonic acid (0.2 mmol) (1:2:2 ratio);

12

8d) domperidone (0.25 mmol)-HP β CD (0.5 mmol)-threonic acid (0.2 mmol) (1:2:2 ratio);

Spectrophotometric determination of domperidone in the four complexes gave 27.7%, 23.4%, 14.5% and 12.5%, respectively.

EXAMPLE 9

Preparation of astemizole complexes

With a process similar to the one of the preceding examples, the following complexes were prepared:

10 9a) astemizole (7.6 mmol)- β CD (6 mmol)-acetic acid (30 mmol).

UV Spectrophotometric determination of astemizole gave 33.9%.

15 9b) astemizole (7.6 mmol)- β CD (8 mmol)-malic acid (1.5 mmol).

UV Spectrophotometric determination of astemizole gave 25.6%.

9c) astemizole (7.6 mmol)- β CD (8 mmol)-L(+) tartaric acid (27 mmol).

20 UV Spectrophotometric determination of astemizole gave 22.5%.

25 Solubility characteristics of the complexes were determined in several systems: distilled water, phosphate buffer (pH 7.6), hydrochloric acid solution (pH 1.3).

Subsequent 0.1 ml portions of the dissolving medium were added to 200 mg of the complex, until a clear or slightly opalescent solution was obtained. After stirring and/or ultrasonication of the samples, astemizole concentrations were calculated in the solutions, whose pH was also measured.

30

Solubility data of the complex with tartaric acid are reported in Table 1.

EXAMPLE 10

Preparation of ketoconazole complexes.

With a process similar to the one of the preceding examples, the following complexes were prepared:

10a) ketoconazole (1 mmol)- β CD (1.5 mmol)-tartaric acid (1 mmol);

10b) ketoconazole (1 mmol)- β CD (1.5 mmol)-citric acid (1 mmol);

Spectrophotometric determination of ketoconazole in the two complexes gave $21.6 \pm 0.5\%$ and $21.7 \pm 0.5\%$, respectively.

Solubility data of the complex with tartaric acid are reported in Table 1.

EXAMPLE 11

Preparation of tamoxifene complexes.

With a process similar to the one of the preceding examples, the following complexes were prepared:

11a) tamoxifene (1 mmol)- β CD (2 mmol)-tartaric acid (2 mmol),

11b) tamoxifene (1 mmol)- β CD (2 mmol)-citric acid (2 mmol);

11c) tamoxifene (1 mmol)-HP β CD (substitution degree 2.8, 2 mmol)-citric acid (2 mmol).

Tamoxifene content in the complexes resulted $12.2 \pm 0.1\%$; $12.3 \pm 0.1\%$; $11.5 \pm 0.1\%$, respectively.

Solubility data of the complex with β CD and citric acid are reported in Table 2.

EXAMPLE 12**Preparation of clomifene complexes.**

With the same process complexes with clomifene (2.5 mmol), β CD (2.5 mmol), and citric acid (7 mmol) or tartaric acid (5 mmol) were prepared.

Clomifene content resulted $17.9 \pm 0.1\%$ and $18.2 \pm 0.1\%$, respectively.

Solubility data with citric acid are reported in Table 2.

EXAMPLE 13**Preparation of cyclobenzaprine (CBP)- β CD-tartaric acid complex.**

10 mmol of CBP.HCl were neutralized with 10 mmol NaOH and 10 mmol of β CD and 10 mmol of tartaric acid were suspended into 20 ml of water. The resulting clear, viscous solution was freeze dried.

The so obtained product contained 19.6% of CBP base (CBP.B), as determined by UV spectrophotometry.

500 mg of the complex were dissolved in 2.2 ml of water giving 45 mg/ml of CBP.B. After dissolving 100 mg of the above complex in 2, 4, 6, and 8 ml of buffer solution (pH=7.6) the following respective pH values were measured in the solutions: 4.85, 6.5, 7.0, and 7.25. The CBP content of these solutions was 10, 5, 3.3, and 2.5 mg/ml, respectively. No precipitation was observed at any dilution rate.

EXAMPLE 14**Preparation of itraconazole- β CD-hydrochloric acid complex.**

5 mmol of itraconazole, 10 mmol of β CD and 15 mmol of hydrochloric acid were ultrasonicated. The resulting

very thick, homogeneous suspension was then diluted with 80 ml of distilled water and ultrasonication was continued for 20 min. The suspension was freeze dried.

5 The molar ratio of the complex was 1:2:2: with approximately 20% w/w itraconazole content.

The solubility of the complex in distilled water was appropriate. Equilibration of 100 mg of the complex in 2 ml of distilled water for 2-5 min resulted in more than 5 mg/ml of dissolved itraconazole, that means more
10 than 20.000 fold solubility enhancement.

Table 1: Water solubility at room temperature of some basic type drugs, their acid salts, their complexes with β -CD, their salts in β -CD solution and multicomponent complexes, expressed as drug concentration F (mg/ml).

	FB	FB/AT	FB/ β CD	FT/ β CD	FB/AT/ β CD
TERFENADINE	0.010	0.340	0.080	3.3	50
	[1x]	[34x]	[8x]	[330x]	[5000x]
ASTEMIZOLE	0.004	3.270	0.065	7.9	90
	[1x]	[817.5x]	[16x]	[1975x]	[22500x]
DOMPERIDONE	0.005	10	0.022		25
	[1x]	[2000x]	[4.4x]		[5000x]
KETOCONAZOLE	0.050	21	1.24	21	110
	[1x]	[420x]	[27x]	[420x]	[2200x]
CINNARIZINE	0.1	9	0.5		20
	[1x]	[90x]	[5x]		[2000x]
FB Basic-type drug					
AT Tartaric acid					
β CD β -Cyclodextrin					
FT Drug tartrate					

Table 2: Water solubility at room temperature of some basic type drugs, their acid salts, their complexes with β -CD, their salts in β -CD solution and multicomponent complexes, expressed as drug concentration F (mg/ml).

	FB	FB/AC	FB/CD	FC/ β CD	FB/AC/ β CD
TAMOXIFENE	0.03	0.3	0.06	11	20
	[1x]	[10x]	[2x]	[366x]	[666x]
CLOMIFENE	0.04	6.2	0.28	20	77
	[1x]	[155x]	[7x]	[500x]	[1925x]
TERFENADINE	0.01	0.76	0.08	4.2	50
	[1x]	[76x]	[8x]	[420x]	[5000x]
FB Basic-type drug					
AC Citric acid					
β CD β -Cyclodextrin					
FT Drug citrate					

18

Table 3: Water solubility of some basic type drugs, their complexes with a CD and multicomponent complexes, expressed as drug concentration F (mg/ml).

5	DRUG			
		TERFENADINE	DOMPERIDONE	ASTEMIZOLE
	FB	0.01	0.005	0.004
	FB/ α -CD	-	0.033 (6.6x)	0.024 (6x)
10	FB/AT/ α -CD	-	25 (5000x)	-
	FB/ γ -CD	-	0.04 (8x)	0.027 (6.6x)
15	FB/AT/ γ -CD	30 (3000x)	30 (6000x)	-
	FB/HP β -CD	1.23 (123x)	0.16 (32x)	0.353 (86x)
	FB/AT/HP β -CD	60 (6000x)	50 (10000x)	-
20	FB/DIMEB	2.32 (232x)	0.56 (112x)	1.245 (303x)
	FB/AT/DIMEB	60 (6000x)	30 (600x)	-
25	FB/RAMEB	4.50 (450x)	0.28 (56x)	1.10 (275x)
	FB/AT/RAMEB	60 (6000x)	30 (6000x)	-
	FB	Basic-type drug		
30	AT	Tartaric acid		
	α -CD	α -Cyclodextrin		
	γ -CD	γ -Cyclodextrin		
	HP β -CD	Hydroxypropyl- β -Cyclodextrin		
	DIMEB	Dimethyl- β -cyclodextrin		
35	RAMEB	RANdom METHylated β -Cyclodextrin		

From the results reported in the above Tables 1, 2 and 3 the remarkable solubility enhancement obtained with the complexes of the present invention, may be observed.

5 This solubility enhancement is very important not only for the improvement of the biopharmaceutical characteristics of the compounds, but also for their bioavailability.

10 The presence in the complex of an excess amount of acid creates an acid environment which facilitates the dissolution of the drug also at high pH values, so that the dissolution characteristics of the compound are less dependent on the local pH.

15 Also in view of pharmaceutical technology, the advantages are remarkable. In fact, liquid pharmaceutical compositions, such as vials, drops, oral solutions, may be prepared also with hardly soluble drugs. Said compositions are a further object of the present invention.

20 As example, water amounts (ml) necessary to solubilize one unitary dose of terfenadine equal to 60 mg in different systems are reported.

System	Water amount (ml)
Terfenadine	6.000
25 Terfenadine tartrate (79.2 mg)	176
Terfenadine- β -CD complex 1:2 (349 mg)	750
Terfenadine tartrate- β -CD complex 2:1 (380 mg)	18
Terfenadine-tartaric acid- β -CD complex (353-400 mg)	1.2

30 Accordingly, the present invention provides the surprising use of β -CD as solubilizing agent in

20

parenteral pharmaceutical compositions. Heretofore, said use has been hindered from the technological point of view by the low water solubility in comparison with the normal solutions volumes used in this kind of compositions.

EXAMPLE 15

Effect of some acids on the β -CD solubility.

In a test tube 1000 mg of β -CD in 5 ml of a solution having different concentrations of an acid selected from tartaric, citric, lactic acid, were let to equilibrate for two days at 28 \pm 2°C under stirring. The solution was filtered and β -CD concentration was determined by HPLC.

The results are reported in Table 4.

Table 4

	ACID	ACID CONCENTRATION	β -CD CONCENTRATION
		(mg/ml)	(mg/ml)
20	Tartaric	0	18.3
		7.5	28.0
		15.0	31.4
		37.5	44.4
		75.0	65.4
		112.5	83.7
25	citric	0	18.3
		9.6	34.1
		19.2	47.9
		48.0	86.1
		96.0	140.1
		144.0	195.7

- (continued) -

Table 4 (continued)

ACID	ACID CONCENTRATION	β -CD CONCENTRATION
	(mg/ml)	(mg/ml)
lactic	0	18.3
	4.5	17.1
	9.0	18.8
	22.5	24.2
	45.0	31.0
	67.5	35.8

Hydroxyacids (tartaric and citric acid) remarkably enhance the water solubility of β -CD, depending on their concentration.

Lactic acid instead exerts a lower effect even if it is effective in the formation of multicomponent complexes, as shown in the examples.

In fact, the surprising enhancement of the β -CD solubility in the multicomponent complexes should not exclusively be attributed to the effect of the acid.

In the multicomponent complexes of terfenadine and tartaric or citric acid, for example, the concentration of β -CD is about 150 mg/ml, about 8 times higher than water solubility of β -CD as such.

In the binary system acid- β -CD, in the presence of the same acid concentrations, namely 11 and 17 mg/ml respectively, the increase of the β -CD solubility is about 2 times.

Some cyclodextrins may be used not only as complexing agents, but also as solubilizing agents in the preparation of liquid pharmaceutical compositions.

Among these, the most used one appears to be HP β -CD.

Also in this case the technological advantages, which are connected with the use of the complexes according to the present invention, appears evident.

5 Accordingly, not only higher drug concentrations in solution are obtained, but also with the same amount of dissolved drug, the amount of cyclodextrin is considerably reduced.

10 Table 5 shows the amounts of HP β -CD necessary for the solubilization of the same amount of drug depending on the use of cyclodextrin in a multicomponent complex or as conventional solubilizing agent.

Table 5: HP β -CD amount (mg), in the form of multicomponent complex or of conventional solubilizing agent, necessary to solubilize 10 mg of Terfenadine or Domperidone or 100 mg of Ketoconazole, respectively. The drug content in the complex or the drug concentration in the solution are reported within brackets.

	Drug amount (F) (mg)	HP β -CD content (mg)	
Terfenadine-HP β -CD-tartaric acid multicomponent complex (F=14%)	10	57.3	23
Terfenadine-10% HP β -CD solution (F=1.23 mg/ml)	10	803	
Domperidone-HP β -CD-tartaric acid multicomponent complex (F=14%)	10	57.3	
Domperidone-10% HP β -CD solution (F=0.16 mg/ml)	10	6240	

- (continued) -

Table 5 (continued)

	Drug amount (F) (mg)	HP β -CD content (mg)
Ketoconazole-HP β -CD-tartaric acid multicomponent complex (F=20%)	100	375
Ketoconazole-HP β -CD solution* (F=25 mg/ml in 60% HP β -CD)	100	2400

* solution added with 10% propylene glycol and HCl to pH 2.1.
F=Drug.

25

The remarkable decrease of the HP β CD amount, necessary to the drug solubilization using the complexes of the present invention, is advantageous also from a toxicological point of view, particularly
5 for parenteral formulations.

Finally, the simplicity of the technology of preparation of the complexes of the present invention, which represents a further advantage for the industrial applicability, is to be underlined.

10

CLAIMS

1. Multicomponent inclusion complexes characterized in that a basic-type drug (guest molecule), an acid and a cyclodextrin are present.
2. Inclusion complexes according to claim 1, characterized in that both the guest molecule and the cyclodextrin have a very high water solubility.
3. Inclusion complexes according to claim 1, characterized in that the acid increase both the drug and the cyclodextrin water solubility.
4. Inclusion complexes according to claim 1, characterized in that an aliphatic carboxylic acid bearing on or more oxygenated substituents in the aliphatic chain, preferably keto groups or hydroxy groups is the acid.
5. Inclusion complexes according to claim 4, characterized in that the acid is selected from the group consisting of citric acid, tartaric acid, α -ketoglutaric acid, threonic acid
6. Inclusion complexes according to claim 1, characterized in that hydrochloric acid is the acid.
7. Inclusion complexes according to claim 1, characterized in that cyclodextrin is selected from the group consisting of α -, β - or γ -cyclodextrin, hydroxypropyl- β CD, dimethyl- β CD, RAMEB (RANDOM METHYLATED β -CD) or other cyclodextrin derivatives.
8. Inclusion complexes according to claim 1, characterized in that the basic-type drug is selected from the group consisting of terfenadine, astemizole, domperidone, ketoconazole, cinnarizine, tamoxifene,

clomifene, cyclobenzaprine, itraconazole.

9. A process for the preparation of multicomponent inclusion complexes of the preceding claims comprising the following steps:

- 5 a) suspension in distilled water of suitable quantities of drug, cyclodextrin and acid ;
 - b) homogenization of the suspension obtained in step a) by stirring and/or sonication to obtain a clear or slightly opalescent solution;
 - 10 c) filtration of the solution obtained in step b) by using a suitable system to obtain a clear solution;
 - d) dehydration of the solution obtained in step c).
10. Pharmaceutical compositions containing a
- 15 multicomponent inclusion complex of claims 1-8.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 94/00205

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 413 528 (YU, RUEY J., DR.) 20 February 1991 see page 32, line 9 - line 14; claims 1,4,7	1-10
X	--- CHEMICAL ABSTRACTS, vol. 111, no. 12, 27 November 1989, Columbus, Ohio, US; abstract no. 197150p, see abstract & JP,A,1 138 202 (ENSUIKO SUGAR REFINING CO.) 31 May 1989	1
Y	--- -/--	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

1 June 1994

Date of mailing of the international search report

16.06.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/EP 94/00205

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 10, no. 31 (C-327) (2088) 6 February 1986 & JP,A,60 185 772 (MITSUI SEIYAKU KOGYO K.K.) 21 September 1985 cited in the application see abstract ----	1-5,7,9, 10
X	J. INCLUSION PHENOMENA, vol.2, no.3,4, 1984 pages 511 - 521 T. TOKUMURA ET AL. 'INCLUSION COMPLEX OF CINNARIZINE WITH BETA-CYCLODEXTRIN IN AQUEOUS SOLUTION AND IN SOLID STATE.' cited in the application see page 518, paragraph 3; figure 8 ----	1-5,7-10
X	J. INCLUSION PHENOMENA, vol.3, 1985 pages 71 - 84 AGNES STADLER-SZÖKE ET AL. 'FENDILINE-BETA-CYCLODEXTRIN INCLUSION COMPLEX.' cited in the application see page 81 - page 82; figure 9 -----	1-4,6,7, 9,10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 94/00205

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-4, 10
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
In view of the large number of compounds, which are designed by terms such as, basic-type drug or acid (see claim 1) the search has to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given(please see annex)
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/210

.... and/or the compounds mentioned in the claims or examples.
(see guidelines, Part B, Chapter III, paragraph 3.6)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Application No

PCT/EP 94/00205

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0413528	20-02-91	US-A- 5091171 AU-A- 5913990 CA-A- 2019273	25-02-92 21-02-91 15-02-91
JP-A-1138202	31-05-89	NONE	